Lilly's Foundayo Meets Heart-Safety Goals in Largest Type 2 Diabetes Trial

What Happened

Eli Lilly has disclosed the fullest dataset yet from ACHIEVE-4, the largest and longest Phase 3 study of its oral GLP-1 receptor agonist Foundayo (orforglipron) in adults with type 2 diabetes. The trial tested the once-daily pill against titrated insulin glargine in adults with type 2 diabetes and obesity or overweight who carried elevated cardiovascular risk.

Foundayo met its primary endpoint, demonstrating noninferior risk of major adverse cardiovascular events (MACE-4) versus insulin glargine — a 16% lower observed risk of the four-way composite of cardiovascular death, heart attack, stroke or hospitalization for sudden unstable chest pain.

Prespecified analyses went further:

• A 23% lower risk of MACE-3, the composite of cardiovascular death, heart attack or stroke
• A 53% lower risk of cardiovascular death and a 57% lower risk of all-cause mortality compared with insulin glargine
• An A1C reduction of 1.6 percentage points from a baseline of 8.22%, versus a 1.0-point reduction on insulin
• Average weight loss of 8.8% — roughly 18 pounds — versus a 1.7% weight gain on insulin, with more than a third of Foundayo patients losing at least 10% of body weight against 3% of insulin patients
• Improvements in waist circumference, systolic blood pressure and non-HDL cholesterol, plus a slower observed decline in kidney function

In a separate post-hoc analysis of the ATTAIN-1 study, the same oral agent was associated with an estimated 57% reduction in predicted type 2 diabetes risk and an 18% reduction in predicted cardiovascular disease risk versus placebo in adults with obesity-related comorbidities.

Who Is Affected

• Adults with type 2 diabetes and obesity or overweight at elevated cardiovascular risk — the enrolled population
• Patients on injectable therapy, for whom a pill with insulin-comparable cardiovascular safety could reorder the treatment ladder
• Cardiometabolic researchers, who now have long-horizon cardiovascular data for an oral agent
• The wider obesity-medicine market, as Lilly plans a U.S. type 2 diabetes submission, adding to the drug's existing weight-management approval

Timeline

• Earlier this year — Lilly announces topline ACHIEVE-4 results, with the primary endpoint met
• This week — the complete dataset is presented, adding mortality, kidney-function and metabolic-marker analyses
• Ongoing — ATTAIN-OUTCOMES, a dedicated cardiovascular-outcomes Phase 3 trial in adults with established cardiovascular or kidney disease, continues toward readout
• Next — a planned U.S. regulatory submission in type 2 diabetes

What This Means for Researchers

Two observations stand out. First, ACHIEVE-4 is the most extensive cardiovascular dataset yet published for a non-peptide, orally active GLP-1 agonist — a small molecule engineered for oral bioavailability rather than a modified injectable peptide. Noninferiority against an active insulin comparator in a high-risk population is a meaningful benchmark for the entire oral-agonist class.

Second, the mortality findings should be read as hypothesis-generating: they were prespecified but sit outside the trial's primary hierarchy, and ATTAIN-OUTCOMES is the study designed to answer the outcomes question definitively.

How to Verify Your Peptides

Whatever happens in the branded market, research-grade GLP-1 products circulate widely — and crude copies of newer oral agents are already inevitable. If you source compounds for research:

• Read how independent lab testing works
• See worked examples in semaglutide purity testing and HPLC testing for tirzepatide
• Choose a facility from our guide to trusted third-party testing labs

Safe Alternatives

For compound research, our semaglutide and tirzepatide profiles summarize published clinical data and adverse-event signals, and our vetted vendor directory lists suppliers that publish third-party lab results.

Sources

Company clinical trial disclosures and regulatory announcements; industry reports.